U0126 treatment inhibited proliferation by 70% and 76% in RT112 or T24 cells, respectively

U0126 treatment inhibited proliferation by 70% and 76% in RT112 or T24 cells, respectively. efficiently. Crosstalk between PI3K and the MAPK signaling pathway is usually mediated via PI3K and indirect by S6K1 activity. Inhibition of MEK1/2 results in activation of Akt but not mTOR/S6K1 or 4E-BP1. Our data suggest that 4E-BP1 is a potential new target molecule and stratification marker for anti cancer therapy in UC and support the concern of a multi-targeting approach against PI3K, mTORC1/2 and MAPK. == Introduction == Bladder cancer is the fifth most common cancer world-wide with an estimated 357.000 new cases and 145.000 deaths in 2010[1]. Urothelial carcinoma (UC) representing 90% of all bladder tumors are a heterogenous entity comprised of papillary tumors and solid invasive carcinomas which require radical treatment once they have progressed into the muscular layer of the bladder. If untreated, about 85% of patients with invasive bladder tumor will pass away from disease progression within two years from diagnosis[2]. Radical cystectomy with pelvic lymph node dissection is the standard of care for muscle-invasive bladder cancer. With this approach 5-12 months progression-free survival probabilities of 6568% can be achieved across all tumor stages[3],[4]. Despite improvements in cisplatin-based chemotherapy for patients with metastatic disease, the median overall 5-year survival time is limited to 1415 weeks[5]. Thus, new therapeutic methods are highly desired. Better knowledge about aberrant activation of cell signaling pathways that are involved in tumorigenesis of the bladder might provide suitable molecular targets for novel therapies[6],[7],[8]. One such pathway is the PI3K/Akt/mTOR signaling pathway that has been linked to tumorigenesis in many tissues[9],[10]. Normally, upon activation by tyrosine receptor kinases or RAS proteins PI3K converts phosphatidylinositol-4,5-bisphosphate (PIP2) into phosphatidylinsositol-3,4,5-trisphosphate (PIP3). This reaction can be reversed by the PI3K antagonist PTEN (phosphatase and tensin homologue deleted on chromosome 10). PIP3recruits PDK1 (protein dependent kinase 1) to the cell membrane where it binds and phosphorylates Akt at amino acid residue T308. Akt is considered as the most critical signaling node in this pathway regulating various substrates affecting cellular processes involved in the control of cell growth and survival[11]. Akt signaling converges through the tuberous sclerosis proteins 1/2 (TSC1/2) and the small GTPase Rheb on mTOR, a serine/threonine kinase that forms two unique protein complexes with either raptor (regulatory-associated protein of mTOR) yielding mTORC1 or rictor (rapamycin insensitive companion of mTOR) yielding mTORC2[10]. mTORC2 can be activated by PI3K directly and phosphorylates Akt at S473, which together with phosphorylation at T308 results in the full activation of Akt[12],[13]. Akt phosphorylated IWP-3 at S473 has been associated with poor prognosis in many cancers including those of the pancreas, liver, prostate and breast[13]. The best-defined substrates of mTORC1 are the kinases p70S6K1 (S6K1) and eIF4E-binding protein 1 (4E-BP1), both of which are important in the control of protein translation initiation[14],[15],[16]. Dephosphorylated 4E-BP1 can bind to the elF4E protein complex to prevent cap-dependent translation and plays an important role in mediating signaling events of the PI3K and MAPK pathway in tumors[15]. Phosphorylated S6K1 is IWP-3 required for translation of 5 terminal oligopyrimidine (TOP) FLJ39827 mRNAs. Dephosphorylation of S6K1 results in a feedback loop that results in upregulation of receptor tyrosine kinases or insulin receptor substrate proteins (IRS), which then activate the PI3K and also the MAPK signaling pathway[17],[18]. Crosstalk between the PI3K and the MAPK signaling network occurs also by way of RAS and ERK1/2, activating PI3K and additionally mTORC1 through TSC1/2[19],[20],[21],[22]. IWP-3 mTORC1 can be selectively inhibited by rapamycin, a macrolide antibiotic, that in a complex with the cytosolic protein FKBP12 inhibits mTORC1 and at higher concentrations also mTORC2[23],[24]. Novel mTOR inhibitors in clinical use such as everolimus (RAD001) or temsirolimus (CCI-779) are derivatives of rapamycin. Administered as anti-tumor drugs, the response rates in patients differ from 030% dependent on the tumor[25]. It is suspected that this major limitation in the clinical software of mTOR inhibitors results from the mTORC1-S6K1-PI3K feedback loop. This resulted in the development of inhibitors that target both, PI3K.